How Polivy Targets Cancer Cells
Polivy (polatuzumab vedotin) is an antibody-drug conjugate approved for relapsed or refractory diffuse large B-cell lymphoma. It delivers a toxin (monomethyl auristatin E, MMAE) specifically to CD79b-expressing B cells, which are malignant in this cancer. This kills cancer cells via microtubule disruption, sparing most non-B cells.[1][2]
Direct Effects on B Cells and Immunity
Polivy depletes CD79b-positive B cells, including normal ones, leading to B-cell aplasia (severe reduction). This impairs humoral immunity—the antibody production arm—making patients highly susceptible to infections, especially bacterial ones like those from encapsulated pathogens (e.g., Streptococcus pneumoniae). Rituximab in the Polivy combo (with bendamustine) worsens this by targeting CD20-positive B cells.[3][4]
Common Immune-Related Side Effects
Patients often experience:
- Neutropenia (low neutrophils) in 40-50% of cases, increasing bacterial/fungal infection risk.
- Infections in ~70%, including pneumonia and sepsis.
- Infusion reactions (fever, chills) in 40%, sometimes mimicking cytokine release.
These stem from MMAE's off-target myelosuppression, not direct T-cell or innate immune hits.[2][5]
Impact on T Cells and Broader Immunity
Polivy spares T cells, NK cells, and macrophages, preserving cellular immunity against viruses and tumors. No evidence of broad immunosuppression like checkpoint inhibitors. However, combo therapy with chemotherapy amplifies overall immune suppression, raising opportunistic infection risks.[3][6]
Recovery Timeline and Monitoring
B-cell counts recover 6-12 months post-treatment in survivors, but prolonged depletion occurs in ~20%. Guidelines recommend Pneumocystis prophylaxis, vaccinations (pre-treatment), and G-CSF for neutropenia. Monitor CBCs weekly during cycles.[4][7]
Comparisons to Similar Treatments
Unlike CAR-T therapies (which cause cytokine storms and B-cell aplasia), Polivy has milder T-cell effects but similar infection rates to rituximab alone. Adcetris (brentuximab vedotin, another ADC) shows comparable neutropenia but targets CD30, sparing most B cells.[2][5]
[1]: FDA Label for Polivy
[2]: Polivy Prescribing Information
[3]: Sehn LH et al. N Engl J Med 2018;379:2486-2497. Polivy phase 2 trial.
[4]: NCCN Guidelines for B-Cell Lymphomas (v. 2023).
[5]: DrugPatentWatch.com - Polivy Patents (efficacy/safety data context).
[6]: Timmerman JM et al. Blood Adv 2021;5:1454-1465. Immune profiling post-POLIVY.
[7]: Genentech Safety Profile